T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

As a line extension, it expands the blockbuster drug franchise and extends the patent protection for Herceptin—a strategy Roche could apply to other biologics as well. “When we looked at the ...

trastuzumab plus an additional HER2-directed ... Supported by F. Hoffmann–La Roche/Genentech. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

Roche, in partnership with Biogen Idec, developed the first medically approved therapeutic monoclonal antibodies for the treatment of lymphoma (rituximab) and breast cancer (trastuzumab).

As biosimilar competition to Herceptin ramps up, Roche is looking to bolster its position in HER2-positive breast cancer with a new indication for Kadcyla. The Swiss pharma firm has announced that ...

The company expects sales and core earnings to keep growing this year after beating analysts’ expectations for 2024, and the ...

That’s a drop in the ocean compared to the CHF 1.5 billion and CHF 910 million in Herceptin and Perjeta sales, respectively, in the same period, but with Phesgo Roche is looking to the future.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced ...